Eli Lilly Cuts Planned €2.3 Billion Germany Investment, Looks to US
Eli Lilly's Investment Shift: Key Details and Implications
Reduction of Planned Investment in Germany
BERLIN, June 3 (Reuters) - Eli Lilly will halve its originally planned investment of €2.3 billion ($2.67 billion) in Germany, CEO Dave Ricks told the Handelsblatt business daily.
Current Status of Alzey Production Site
Over a billion euros has already been invested in the production site for weight-loss injections in Alzey in the western state of Rhineland-Palatinate, the German business daily reported on Wednesday.
Operational Timeline and Capacity Adjustments
The high-tech plant is still scheduled to begin operations in 2027, albeit at reduced capacity and with half of the planned 1,000 jobs, the report added.
Reallocation of Funds to the US
Ricks said the scrapped investment sum for Germany would go to Pennsylvania in the U.S. or a completely new site.
"Europe isn't completely off the table, but the U.S. makes the most sense," he said.
Context: German Legislation and Market Impact
The decision follows proposed legislation in Germany to cap rapidly growing costs in the statutory health insurance system.
Currency Exchange Rate
($1 = 0.8618 euros)
Reporting Credits
(Reporting by Rachel More; Editing by Emelia Sithole-Matarise)
